Bifogade filer
Infant Bacterial Therapeutics (IBT) to present results of “The Connection Study” at ESPGHAN 2025 in Helsinki
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, The Connection Study, will be presented at the 58th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), taking place in Helsinki, Finland, from May 14–17, 2025.
The study’s clinical findings will be shared in both oral and poster presentations by Prof. Teresa Del Moral (University of Miami, USA) and Prof. Flavia Indrio (University of Foggia, Italy), both of whom have been involved in The Connection Study.
IBT’s presentations will highlight data from IBP-9414, its investigational Live Biotherapeutic Product (LBP) designed to prevent necrotizing enterocolitis (NEC) and reduce all-cause mortality in preterm infants.
ESPGHAN 2025 is a leading international forum for clinicians and researchers in pediatric gastroenterology, hepatology, and nutrition
Presentation Details
Oral Presentation
Title: Effect of IBP-9414 on Time to a Strict Definition of Sustained, Full Enteral Feeding in Very Low Birth Weight Infants: Results from The Connection Study
Presenter: Prof. Flavia Indrio
Date & Time: Thursday, May 15, 2025
Location: Messukeskus Helsinki, Expo and Convention Centre
Oral Presentation
Title: Effect of IBP-9414, a Live Biotherapeutic Product on Necrotizing Enterocolitis in Very Low Birth Weight Infants: Results from The Connection Study
Presenter: Prof. Teresa Del Moral
Date & Time: Thursday, May 15, 2025
Location: Messukeskus Helsinki, Expo and Convention Centre
Poster Presentation
Title: Effects of IBP-9414, a Live Biotherapeutic Product, on Necrotizing Enterocolitis, Full Enteral Feeding, and Mortality in Very Low Birth Weight Infants: Connection Study Results
Presenter: Prof. Teresa Del Moral
Date & Time: Friday, May 16, 2025
Location: Poster Area, ESPGHAN 2025 Congress Hall, e-Poster Station: Station 02
Poster Presentation
Title: IBP-9414, a Live Biotherapeutic Product, Reduces All-Cause Mortality in Very Low Birthweight Infants: Results from The Connection Study
Presenter: Prof. Flavia Indrio
Date & Time: Friday, May 16, 2025
Location: Poster Area, ESPGHAN 2025 Congress Hall, e-Poster Station: Station 05
Further details about the ESPGHAN 2025 Meeting can be found at www.espghancongress.org
About The Connection Study
The Connection Study is the largest randomized, double-blind, parallel-group, placebo-controlled trial to date evaluating the efficacy and safety of IBP-9414 in premature infants (birth weight 500–1500g) for the prevention of necrotizing enterocolitis (NEC) — a life-threatening gastrointestinal disease affecting neonates.